Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 42.17 USD 2.6% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
Veracyte Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

328.5
Current
-42.6
Median
4.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
328.5
=
Enterprise Value
3B USD
/
EBIT
9.1m USD
All Countries
Close
Market Cap EV/EBIT
US
Veracyte Inc
NASDAQ:VCYT
3.3B USD 328.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 722.5
US
Abbvie Inc
NYSE:ABBV
314.7B USD 23.7
US
Amgen Inc
NASDAQ:AMGN
147.4B USD 31.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD 26
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10
US
Epizyme Inc
F:EPE
94.1B EUR -501.6
AU
CSL Ltd
ASX:CSL
135.4B AUD 25.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 18
US
Seagen Inc
F:SGT
39.3B EUR -53.1
NL
argenx SE
XBRU:ARGX
34.3B EUR -75.8
EBIT Growth
US
Veracyte Inc
NASDAQ:VCYT
Average EV/EBIT: 66.2
328.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 722.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
31.3
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.6 N/A
AU
CSL Ltd
ASX:CSL
25.6
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.1 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.8 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-853.9
2-Years Forward
EV/EBIT
163.5
3-Years Forward
EV/EBIT
51.4

See Also

Discover More